Siren L.L.C. Purchases 182,485 Shares of Palvella Therapeutics, Inc. $PVLA

Siren L.L.C. boosted its holdings in Palvella Therapeutics, Inc. (NASDAQ:PVLA) by 243.3% during the 1st quarter, HoldingsChannel.com reports. The fund owned 257,485 shares of the company’s stock after buying an additional 182,485 shares during the period. Siren L.L.C.’s holdings in Palvella Therapeutics were worth $32,096,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Summit Partners Public Asset Management LLC increased its holdings in shares of Palvella Therapeutics by 1,016.0% in the 4th quarter. Summit Partners Public Asset Management LLC now owns 389,420 shares of the company’s stock worth $40,761,000 after purchasing an additional 354,525 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Palvella Therapeutics by 202.0% in the third quarter. Vanguard Group Inc. now owns 494,656 shares of the company’s stock worth $31,010,000 after purchasing an additional 330,847 shares during the last quarter. State Street Corp lifted its holdings in shares of Palvella Therapeutics by 206.3% during the fourth quarter. State Street Corp now owns 420,462 shares of the company’s stock valued at $44,010,000 after purchasing an additional 283,211 shares in the last quarter. Jennison Associates LLC lifted its holdings in shares of Palvella Therapeutics by 262.4% during the fourth quarter. Jennison Associates LLC now owns 387,483 shares of the company’s stock valued at $40,558,000 after purchasing an additional 280,573 shares in the last quarter. Finally, Millennium Management LLC purchased a new stake in shares of Palvella Therapeutics during the first quarter valued at $7,553,000. 40.11% of the stock is currently owned by hedge funds and other institutional investors.

Palvella Therapeutics Stock Performance

Palvella Therapeutics stock opened at $143.21 on Friday. Palvella Therapeutics, Inc. has a one year low of $34.57 and a one year high of $161.38. The stock has a fifty day moving average of $126.58 and a 200 day moving average of $116.41. The stock has a market cap of $2.05 billion, a PE ratio of -34.34 and a beta of -0.20.

Palvella Therapeutics (NASDAQ:PVLA) last announced its earnings results on Thursday, May 7th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.30). As a group, sell-side analysts predict that Palvella Therapeutics, Inc. will post -5.26 EPS for the current fiscal year.

Insider Activity

In related news, COO Kathleen Goin sold 4,302 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $110.73, for a total value of $476,360.46. Following the transaction, the chief operating officer owned 2,154 shares of the company’s stock, valued at approximately $238,512.42. This trade represents a 66.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 17.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Wall Street Zen downgraded Palvella Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Palvella Therapeutics in a report on Monday, June 29th. Chardan Capital reiterated a “buy” rating and issued a $240.00 price target on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Stephens reiterated an “overweight” rating and issued a $220.00 price target on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Finally, HC Wainwright reissued a “buy” rating and set a $270.00 price objective on shares of Palvella Therapeutics in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $199.53.

Palvella Therapeutics Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.